



# First Annual Meeting

23<sup>rd</sup> and 30<sup>th</sup> March 2021 - On line Meeting

## DAY 1 - 23<sup>rd</sup> March 2021

**13.15-14.00 Pre-meeting with the EU officer**  
Coordinator, Innovation Acta and whoever wants to attend

### SCIENTIFIC MEETING

All beneficiaries, Fellows, Partner Organisations, Members of Advisory Board

**14.00-14.15 Coordinator's Introduction and project presentation**  
Sebastien Lacroix-Desmazes - Institut national de la santé et de la recherche médicale, France

**14.15-14.45 Partner Organisations presentation (Option)**  
The scientist-in-charge of Partner Organisations should briefly present their research team and describe their role within the network.

**14.45-16.05 Fellows presentation of research projects (20 min each, 15 min pres+5 min questions)**  
The Fellows will briefly present themselves, their background, the general research in hosting labs and their research projects with first results (if any)

- **Monitoring FVIII-specific T-cell responses in healthy individuals and in HA patients**  
Valeria Porcheddu (ESR8) - Commissariat à l'énergie atomique et énergies alternatives, France
- **Delineation of HLA-DP4-restricted FVIII peptidome**  
Mariosaria Miranda (ESR2) - Stichting Sanquin Bloedvoorziening, The Netherlands
- **High-throughput B-cell epitope profiling**  
Puneet Tomar (ESR3) - Università degli Studi di Milano, Italy
- **Intracellular fate of endogenous FVIII variants and association with MHC**  
Payal Suresh Chawla (ESR5) - Universitätsklinikum Bonn, Germany

**16.05-16.35 Discussion on pre-clinical models and candidate FVIII peptides**





# First Annual Meeting

23<sup>rd</sup> and 30<sup>th</sup> March 2021 - On line Meeting

## DAY 2 - 30<sup>th</sup> March 2021

### SCIENTIFIC MEETING

All beneficiaries, Fellows, Partner Organisations, Members of Advisory Board

**14.00-15.00** **Fellows presentation of research projects** (20 min each, 15 min pres+5 min min questions)  
The Fellows will briefly present themselves, their background, the general research in hosting labs and their research projects with first results (if any)

- **Induction of neonatal Fc receptor-mediated tolerance to therapeutic FIII in HA**  
Alejandra Reyes Ruiz (ESR1) - Institut national de la santé et de la recherche médicale, France
- **Induction of tolerance to therapeutic factor VIII by modification with  $\alpha$ 2,3 sialic acid**  
Eleonora Nardini (ESR6) - Stichting VUmc, The Netherlands
- **Tolerance induction towards FVIII using CAR-transduced Tregs**  
Sarah Scatigna (ESR4) - Johan Wolfgang Goethe-Universität Frankfurt am Main, Germany

**15.00-15.30** **General discussion and conclusions by project coordinator**  
Sebastien Lacroix-Desmazes - Institut national de la santé et de la recherche médicale, France

### SUPERVISORY BOARD MEETING

Beneficiaries, Partner Organisations, ESR representative

**15.30-16.00** **Project coordinator**

- **Progress of the project**
- **Potential issues in project activities, go/no go decisions**
- **Strengthen networking and collaboration**
- **Plans for next months: secondments, next events to be organised**
- **Elect ESR representative**

Sebastien Lacroix-Desmazes - Institut national de la santé et de la recherche médicale, France

**16.00-16.15** **INN-ACTA**

- **Schedule of project reporting**
- **Other project commitments: open access to research data, ethics deliverables, outreach and dissemination activities**

Paola Cesaroni and Gabriella Dessole - Innovation Acta Srl, Italy

**16.15 -17.00** **General discussion and conclusions**  
In presence of the EU officer



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 859974.

Organization and  
Graphic project by:  
**Inn·Acta**